AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

STAA · NASDAQ · Medical - Instruments & Supplies

STAAR Surgical (STAA)

Builds implantable lenses used in refractive surgery for vision correction.

$20.43

vs last close−0.22 (−1.07%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Jan 2026	Q1 FY26Apr 2026	Q2 FY26Jul 2026
Revenue	80	76	77	99	89	49	43	44	95	58	94	94
Cost of revenue	17	16	16	21	20	17	15	12	17	14	26	24
Gross profit	64	61	61	78	68	32	28	33	78	44	68	70
	57	50	63	67	63	60	85	63	59	55	50	60
Research & development	11	11	13	12	14	12	14	10	9	9	10	10
	46	39	50	55	48	48	49	47	44	45	40	50
Selling & marketing	27	23	27	31	27	26	25	26	23	26	23	27
General & administrative	19	17	23	24	22	21	24	21	21	20	17	23
Other expenses	0	0	0	0	0	0	23	5	6	0	0	0
Operating income	6	10	−2	12	6	−28	−57	−30	18	−11	17	10
	0	3	0	−2	7	−2	3	4	0	−10	−9	1
Interest income	2	2	2	1	1	2	1	1	1	1	1	0
Other non-operating income	0	−3	0	2	−7	2	−23	−5	−6	10	9	−1
Income before tax	7	14	−2	10	13	−30	−54	−26	19	−21	8	11
Income tax expense	2	6	1	3	3	4	0	−9	10	−2	3	3
Net income from continuing operations	5	8	−3	7	10	−34	−54	−17	9	−18	5	8
Net income	5	8	−3	7	10	−34	−54	−17	9	−18	5	8
EPS, basic	$0.10	$0.16	−$0.07	$0.15	$0.20	−$0.69	−$1.10	−$0.34	$0.18	−$0.36	$0.10	$0.16
EPS, diluted	$0.10	$0.16	−$0.07	$0.15	$0.20	−$0.69	−$1.10	−$0.34	$0.18	−$0.36	$0.10	$0.16
Weighted average shares, basic	49	49	49	49	49	49	49	50	50	50	50	50
Weighted average shares, diluted	49	49	49	50	50	49	49	50	50	50	51	52
EBITDA	8	15	−1	12	15	−28	−32	−23	26	−18	10	13
Depreciation & amortization	1	1	1	2	2	2	2	2	2	2	2	2
EBIT	6	14	−2	10	13	−30	−35	−25	24	−21	8	11